Hormonal
Familial Combined Hyperlipidemia (FCHL) is a common genetic subtype of the metabolic syndrome characterized by disproportionately elevated Apo B levels, which significantly increases the risk of premature coronary artery disease compared to the metabolic syndrome alone.
If you have metabolic syndrome, ask your doctor to check your Apo B levels. If they are high, you may have Familial Combined Hyperlipidemia (FCHL), a genetic condition that puts you at much higher risk for heart disease than metabolic syndrome alone. This diagnosis is crucial because it often requires more aggressive treatment, such as lipid-lowering therapy, to prevent heart attacks.
The second, familial combined hyperlipidemia, accounts for an additional 10–20% of premature CAD. Familial combined hyperlipidemia is characterized by the metabolic syndrome in addition to a disproportionate elevation of apolipoprotein B levels.
Why this rating
Supported by population-based studies and genetic analysis cited in the review.
Source
Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk
Molly C. Carr et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2004-0432
More from this paper
- Abdominal (visceral) obesity is an independent risk factor for coronary artery disease, hypertension, stroke, and type 2 diabetes, driven by a specific dyslipidemia phenotype characterized by hypertriglyceridemia, reduced HDL, and increased small, dense LDL particles.Strong
- Measuring Apolipoprotein B (Apo B) is a superior predictor of cardiovascular risk compared to standard LDL cholesterol in patients with the metabolic syndrome, as it accurately reflects the total number of atherogenic particles.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →